Loading…
Heron Therapeutics, Inc. is projected to decline to $0.8772 by 2027, a -4% move from its current price of $0.9098. HRTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.8742 | $0.9092 | $0.9456 | -0.07% |
| May 30 | $0.8596 | $0.9086 | $0.9604 | -0.13% |
| May 31 | $0.8484 | $0.908 | $0.9718 | -0.20% |
| Jun 1 | $0.839 | $0.9074 | $0.9815 | -0.26% |
| Jun 2 | $0.8307 | $0.9068 | $0.99 | -0.33% |
| Jun 3 | $0.8232 | $0.9062 | $0.9976 | -0.39% |
| Jun 4 | $0.8164 | $0.9057 | $1.00 | -0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8164 | $0.9057 | $1.00 | -0.46% |
| Week 2 | $0.7785 | $0.9015 | $1.04 | -0.91% |
| Week 3 | $0.7498 | $0.8974 | $1.07 | -1.36% |
| Week 4 | $0.7259 | $0.8933 | $1.10 | -1.81% |
| Week 5 | $0.7051 | $0.8893 | $1.12 | -2.26% |
| Week 6 | $0.6865 | $0.8852 | $1.14 | -2.70% |
| Week 7 | $0.6696 | $0.8812 | $1.16 | -3.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapies. It uses its proprietary Biochronomer drug delivery technology to deliver therapeutic levels of short-acting pharmacological agents over days to weeks with a single administration.
Its products include SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P.
Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Heron Therapeutics, Inc. trades at $0.8588 per share, with a market cap of $162.55M and a market-rank of 3972. The current price sits in a landscape where the near-term outlook shows neutral signals and a path to higher prices appears possible in the years ahead according to the provided forecast.
The current price and market position set a baseline for a multi-year scenario in which the average price in 2026 aligns with the current level ($0.8588) while projecting gradual upside through the late 2020s and into the 2030s, 2040s, and beyond. The forecast includes a broad range of outcomes by year, highlighting potential upside and the elevated volatility that accompanies this equity.
Longer-term, the forecast envisions a shift from neutral to bullish sentiment across the main milestones, with notable upside in 2030 and beyond. The trajectory shows the average price climbing from the low-to-mid single digits toward higher levels by 2050, accompanied by progressively larger ROI figures, though the path includes periods of slower growth and occasional pullbacks.
A major floor 38.1% below — a decisive break under it would weaken the trend.
The nearest floor, 6.6% below — buyers have tended to step in here.
The nearest ceiling, 44.0% above — a clean break opens room to run.
A major ceiling 63.8% above — clearing it would confirm fresh momentum.
Key HRTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HRTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.874 | Buy | $0.8857 | Buy |
| MA 10 | $0.875 | Buy | $0.9099 | Sell |
| MA 20 | $1.03 | Sell | $0.9578 | Sell |
| MA 50 | $0.95 | Sell | $1.00 | Sell |
| MA 100 | $1.09 | Sell | $1.07 | Sell |
| MA 200 | $1.18 | Sell | $1.23 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.12 | Neutral |
| Stoch RSI (14) | 28.49 | Neutral |
| CCI (20) | -47.16 | Neutral |
| Williams %R (14) | -84.62 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -24.79 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 15.38 | Buy |
| TRIX (15) | -0.31 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 56.76 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 0.88 | Buy |
| ADX (14) | 27.23 | Sell |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is BEARISH in the near term. RSI14 is 40, indicating modest momentum weakness, while the 50-day simple moving average is $0.9498 and the 200-day simple moving average is $1.18, suggesting the price is hovering near important moving averages.
Support is identified at $0.85 and resistance at $1.31, framing a tight short-term range around the current level. The 30-day price range spans from $0.6569 to $1.12, reflecting ongoing swings. The stock’s annualized volatility is 80, underscoring elevated swings around the present price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.75 | $0.9098 | $1.06 | 0% | Neutral | |
| $0.6663 | $0.8772 | $1.24 | -4% | Neutral | |
| $0.6446 | $0.8841 | $1.31 | -3% | Neutral | |
| $0.773 | $1.10 | $1.69 | +21% | Bullish | |
| $0.8471 | $1.24 | $1.97 | +36% | Bullish | |
| $0.7922 | $1.19 | $1.95 | +31% | Bullish | |
| $0.8385 | $1.30 | $2.17 | +43% | Bullish | |
| $0.752 | $1.20 | $2.05 | +31% | Bullish | |
| $0.6737 | $1.10 | $1.92 | +21% | Bullish | |
| $0.8477 | $1.41 | $2.52 | +56% | Bullish | |
| $0.9631 | $1.80 | $3.46 | +98% | Bullish | |
| $1.55 | $3.45 | $7.41 | +279% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.75 | $0.9098 | $1.08 | +0.00% |
| June 2026 | $0.7558 | $0.8961 | $1.09 | -1.51% |
| July 2026 | $0.7143 | $0.8573 | $1.07 | -4.33% |
| August 2026 | $0.7131 | $0.8641 | $1.09 | +0.80% |
| September 2026 | $0.7005 | $0.8557 | $1.09 | -0.98% |
| October 2026 | $0.6477 | $0.797 | $1.03 | -6.86% |
| November 2026 | $0.627 | $0.7765 | $1.01 | -2.58% |
| December 2026 | $0.6486 | $0.8082 | $1.06 | +4.09% |
Click any year to see its month-by-month HRTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Heron Therapeutics, Inc.'s 2026 outlook centres on $0.9098, within a $0.75 to $1.06 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, HRTX could reach as high as $1.24, with a base case around $0.8772 and support toward $0.6663 — roughly -4% from $0.9098. Price action looks broadly range-bound.
Expect HRTX to range from $0.6446 to $1.31 through 2028. The $0.8841 average target implies a -3% move from current prices. That is up +1% on the projected 2027 average. A consolidation phase looks the most probable path here.
The HRTX price prediction for 2029 points to an average of $1.10 (low $0.773, high $1.69) — a potential gain of +21% on today's $0.9098. Momentum favours further upside here.
In 2030, HRTX is projected to trade between $0.8471 and $1.97, averaging $1.24 — a potential gain of +36% from today's $0.9098. That is up +13% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Heron Therapeutics, Inc.'s 2031 outlook centres on $1.19, within a $0.7922 to $1.95 range. That is -4% versus the projected 2030 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2032, HRTX could reach as high as $2.17, with a base case around $1.30 and support toward $0.8385 — roughly +43% from $0.9098. Buyers look set to stay in control over this stretch.
Expect HRTX to range from $0.752 to $2.05 through 2033. The $1.20 average target implies a +31% move from current prices. That is -8% versus the projected 2032 average. Momentum favours further upside here.
The HRTX price prediction for 2034 points to an average of $1.10 (low $0.6737, high $1.92) — a potential gain of +21% on today's $0.9098. Buyers look set to stay in control over this stretch.
In 2035, HRTX is projected to trade between $0.8477 and $2.52, averaging $1.41 — a potential gain of +56% from today's $0.9098. That is up +29% on the projected 2034 average. Momentum favours further upside here.
Heron Therapeutics, Inc.'s 2040 outlook centres on $1.80, within a $0.9631 to $3.46 range. That is up +27% on the projected 2035 average. That marks a +98% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, HRTX could reach as high as $7.41, with a base case around $3.45 and support toward $1.55 — roughly +279% from $0.9098. Momentum favours further upside here.
Investing $1,000 in HRTX today (≈ 1,099.142669 HRTX) could be worth
$3,787.04
+$2,787.04 (+279%) by 2050 · US Dollar
Based on the average projected HRTX price of $3.45 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HRTXwould be worth at today's price.
$1,000 invested in HRTX on May 27, 2025 (≈ 529.100533 HRTX) would be worth
$481.38
-$518.62 (-51.9%) today · 0.48× · US Dollar
Based on a HRTX entry price of $1.89 vs. today's $0.9098.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.85 | $1,070.35 | +7.0% |
| 1 month ago | $1.19 | $764.54 | -23.5% |
| 3 months ago | $1.2 | $758.17 | -24.2% |
| 6 months ago | $1.16 | $784.31 | -21.6% |
| 1 year ago | $1.89 | $481.38 | -51.9% |
| All time (5.0y) ago | $13.34 | $68.2 | -93.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HRTX forecast.
Our base-case forecast reaches $1.80 around 2050.
Implied market cap at $1.80: $340.7M
The multi-year forecast calls for a gradual, then accelerating, upside path with key milestones. In 2030, the average price is $1.15 with a min of $0.7753 and a max of $1.84, yielding a 33.7% return impression and a bullish sentiment. The following years show continued upside, with 2031 at $1.11 (min $0.7297, max $1.84; ROI 29.7; bullish) and 2032 at $1.20 (min $0.7649, max $2.03; ROI 39.8; bullish).
By 2035, the average price rises to $1.30 with a max of $2.34 and ROI of 51, supported by a bullish backdrop. The forecast projects further gains in 2040 to an average of $1.64 with a max of $3.20 and ROI of 91, maintaining a bullish stance. In 2050, the average price reaches $3.12 with a max of $6.82 and ROI of 263, continuing the bullish outlook while acknowledging substantial upside potential and risk.
These are estimates, not guarantees, and outcomes will depend on a range of factors. The near-term picture remains mixed with neutral sentiment, while the longer horizon envisions meaningful upside potential along with the associated volatility.
Tap a question to reveal the answer.
2030 forecast: min $0.7753, avg $1.15, max $1.84; ROI 33.7; sentiment BULLISH.
Near term shows neutral sentiment with 2026 avg $0.8588 and ROI 0, while the long-run path indicates bullish momentum with 2030–2050 forecasts showing higher averages and sizable ROIs (for example 2030 avg $1.15; ROI 33.7; 2050 avg $3.12; ROI 263), but the outlook includes periods of slower growth and volatility.
Yes. The 2050 forecast lists a max of $6.82 and an avg of $3.12, with ROI 263 and sentiment BULLISH.
Current price is $0.8588 and market cap is $162.55M, with a rank of 3972.
The 30-day picture is BEARISH with RSI14 at 40; SMA50 at $0.9498 and SMA200 at $1.18. Support is $0.85 and resistance is $1.31; the 30-day range is $0.6569 to $1.12, and annualized volatility stands at 80.
Heron Therapeutics, Inc. Community Discussion
0Share your Heron Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.